Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).
Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.
A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.
Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Exchange of Azathioprine by Mycophenolatmofetile and Cyclosporine A Dose Reduction After Heart Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2009-02-16
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 23
- Registration Number
- NCT00359814
- Locations
- π©πͺ
Hannover Medical School, Department of Thoracic and Cardiovascular Surgery, Hannover, Germany
Withdrawal of Steroids, Cyclosporine A Dose Reduction and Switch to Mycophenolatmofetile After Heart Transplantation
- Conditions
- Interventions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2009-02-13
- Lead Sponsor
- Hannover Medical School
- Target Recruit Count
- 40
- Registration Number
- NCT00359658
- Locations
- π©πͺ
Hannover Medical School, Department of Thoracic and Cardiovascular Surgery, Hannover, Germany
Hematopoietic Stem Cell Transplantation in the Treatment of Infant Leukemia
- Conditions
- Recurrent Childhood Acute Myeloid LeukemiaRefractory Anemia With Excess Blasts in TransformationRefractory AnemiaDe Novo Myelodysplastic SyndromeSecondary Myelodysplastic SyndromeChildhood Myelodysplastic SyndromeLeukemiaMyelodysplastic SyndromesSecondary Acute Myeloid LeukemiaRefractory Anemia With Excess Blasts
- Interventions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 33
- Registration Number
- NCT00357565
- Locations
- πΊπΈ
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States
Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.
- Conditions
- Interventions
- Biological: aldesleukinBiological: filgrastimBiological: natural killer cell (NK) therapyDrug: cyclophosphamideDrug: cyclosporineDrug: fludarabine phosphateDrug: methylprednisoloneDrug: mycophenolate mofetilProcedure: Umbilical Cord Blood Transplantation (UCBT)Radiation: Total body irradiation (TBI)
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 16
- Registration Number
- NCT00354172
- Locations
- πΊπΈ
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Cyclophosphamide, Antithymocyte Globulin, and Total-Body Irradiation in Treating Patients With Severe Aplastic Anemia Undergoing Umbilical Cord Blood Transplant
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2011-01-05
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT00354419
- Locations
- πΊπΈ
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant
- Conditions
- Interventions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT00343785
- Locations
- πΊπΈ
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States
πΊπΈFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
πΊπΈFroedtert and the Medical College of Wisconsin, Milwaukee, Wisconsin, United States
A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Childhood Burkitt LymphomaAccelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Anaplastic Large Cell LymphomaChildhood Chronic Myelogenous LeukemiaChronic Phase Chronic Myelogenous Leukemia
- Interventions
- First Posted Date
- 2006-06-23
- Last Posted Date
- 2015-02-11
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00343798
- Locations
- πΊπΈ
University of Colorado Cancer Center - Anschutz Cancer Pavilion, Aurora, Colorado, United States
πΊπΈCity of Hope Medical Center, Duarte, California, United States
πΊπΈFred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis
- Conditions
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2013-09-17
- Lead Sponsor
- Children's Cancer and Leukaemia Group
- Target Recruit Count
- 288
- Registration Number
- NCT00334672
- Locations
- π¬π§
Birmingham Children's Hospital, Birmingham, England, United Kingdom
π¬π§Watford General Hospital, Herts, England, United Kingdom
π¬π§Leeds Cancer Centre at St. James's University Hospital, Leeds, England, United Kingdom
Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia
- Conditions
- Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Myelodysplastic Syndrome With Isolated Del(5q)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Previously Treated Myelodysplastic SyndromesAcute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic SyndromeAcute Myeloid Leukemia/Transient Myeloproliferative DisorderAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Interventions
- Radiation: total-body irradiationProcedure: allogeneic hematopoietic stem cell transplantationDrug: mycophenolate mofetilDrug: cyclophosphamideDrug: cyclosporineDrug: busulfanDrug: fludarabine phosphateProcedure: peripheral blood stem cell transplantationProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationOther: laboratory biomarker analysisGenetic: cytogenetic analysisOther: flow cytometryOther: pharmacological studyGenetic: fluorescence in situ hybridizationDrug: tacrolimusGenetic: polymorphism analysisDrug: methotrexate
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2014-10-31
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT00322101
- Locations
- πΊπΈ
Weill Cornell University, New York, New York, United States
πΊπΈHealthOne Presbyterian St. Lukes Medical Center, Denver, Colorado, United States
πΊπΈEmory University, Altanta, Georgia, United States
Sirolimus and Cyclosporine for Treatment-Resistant Aplastic Anemia
- First Posted Date
- 2006-04-27
- Last Posted Date
- 2008-10-07
- Lead Sponsor
- Office of Rare Diseases (ORD)
- Target Recruit Count
- 52
- Registration Number
- NCT00319878
- Locations
- πΊπΈ
Lee Moffitt Cancer Center, Tampa, Florida, United States
πΊπΈTaussig Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio, United States
πΊπΈUCLA Center for Health Sciences, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.